Drug intelligence / Profile preview

encofosbuvir

Development stage: Phase 2
Lead developer: Sunshine Lake Pharma
Modality: Small Molecules
Administration: Oral

Overview

Encofosbuvir (HEC110114) is a small-molecule nucleotide analog prodrug developed by Sunshine Lake Pharma for the treatment of chronic hepatitis C virus (HCV) infection. As a direct-acting antiviral (DAA), it targets the NS5B RNA-dependent RNA polymerase. Once metabolized into its active triphosphate form, it acts as a defective substrate for the NS5B polymerase, leading to premature viral RNA chain termination. Encofosbuvir demonstrates pan-genotypic activity across HCV genotypes 1 through 6. It was approved in China in March 2025 as part of a domestically produced pan-genotypic regimen, typically co-administered with the NS5A inhibitor netanasvir.

Other names: HEC110114HEC-110114HEC 110114

Targets

NS5B (Hepatitis C virus non-structural protein 5B (NS5B) RNA-dependent RNA polymerase)

Beyond the preview

Go deeper on encofosbuvir.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on encofosbuvir.

Explore the full profile